Literature DB >> 23595399

One-phase treatment for calculous pyonephrosis by percutaneous nephrolithotomy assisted by EMS LithoClast master.

Jian Wang1, Da-qing Zhou, Meng He, Wen-gang Li, Xiang Pang, Xiao-xiang Yu, Bo Jiang.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23595399

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  5 in total

1.  Mini-nephroscope combined with pressure suction: an effective tool in MPCNL for intrarenal stones in patients with urinary tract infections.

Authors:  Guibin Xu; Yongzhong He; Haibo Zhao; Xianhan Jiang; Gang Feng; Weiqing Yang; Wei Xu; Qingling Xie; Xun Li
Journal:  Urolithiasis       Date:  2016-02-09       Impact factor: 3.436

2.  Multiple tracts percutaneous nephrolithotomy assisted by LithoClast master in one session for staghorn calculi: report of 117 cases.

Authors:  Jinbo Chen; Xu Zhou; Zhi Chen; Longfei Liu; Li Jiang; Cheng Chen; Lin Qi; Xiongbing Zu; Hequn Chen
Journal:  Urolithiasis       Date:  2013-12-24       Impact factor: 3.436

3.  A Randomized Study of Minimally Invasive Percutaneous Nephrolithotomy (MPCNL) with the aid of a patented suctioning sheath in the treatment of renal calculus complicated by pyonephrosis by one surgery.

Authors:  Jianrong Huang; Leming Song; Donghua Xie; Monong Li; Xiaolin Deng; Min Hu; Zuofeng Peng; Tairong Liu; Chuance Du; Lei Yao; Shengfeng Liu; Shulin Guo; Jiuqing Zhong
Journal:  BMC Urol       Date:  2016-12-08       Impact factor: 2.264

4.  Multi-tract percutaneous nephrolithotomy combined with EMS lithotripsy for bilateral complex renal stones: our experience.

Authors:  Taisheng Liang; Chenming Zhao; Gang Wu; Botao Tang; Xiangdong Luo; Shangguang Lu; Yu Dong; Huan Yang
Journal:  BMC Urol       Date:  2017-02-28       Impact factor: 2.264

5.  One-stage tubeless percutaneous nephrolithotomy for asymptomatic calculous pyonephrosis.

Authors:  Shijie Guo; Xicai Zhang; Fengyue Li; Chunyue Sun; Yonghe Zhang; Xiande Cao
Journal:  BMC Urol       Date:  2022-03-07       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.